论文部分内容阅读
目的观察分析多西紫杉醇联合替吉奥在治疗蒽环类耐药三阴性乳腺癌(triple-negtive breast cancer,TNBC)中的临床疗效。方法选择2009年6月~2011年6月绍兴市人民医院肿瘤放疗科收治的64例三阴性乳腺癌患者,回顾性分析上述病例的临床资料,所有患者使用蒽环类药物治疗无效或复发,继而选择联合多西紫杉醇、替吉奥治疗,观察分析此种方案的临床疗效和不良反应情况。结果 64例患者的治疗后有效率为54.69%,病情控制率为79.69%,治疗过程中未见死亡病例,主要不良反应为胃肠道反应和骨髓抑制,但患者对此均可耐受;随访结果显示中位疾病进展时间为10.5个月,2年后无疾病进展生存率为0。结论联合多西紫杉醇、替吉奥治疗蒽环类耐药三阴性乳腺癌的临床效果良好,不良反应相对较轻,是较为理想的辅助化疗方案。
Objective To investigate the clinical efficacy of docetaxel combined with tiagacil in the treatment of triple-negative breast cancer (TNBC). Methods Sixty-four patients with triple-negative breast cancer admitted to Department of Radiation Oncology, Shaoxing People’s Hospital from June 2009 to June 2011 were retrospectively analyzed. All of the patients were treated with anthracyclines ineffectively or relapsed Select combined docetaxel, for treatment of Gio, observed and analyzed the clinical efficacy of this program and adverse reactions. Results After treatment, the effective rate was 54.69% in 64 patients, the disease control rate was 79.69%. No deaths were found during the treatment. The main adverse reactions were gastrointestinal reactions and myelosuppression, but patients were tolerant of these. Follow-up The median time to progression was 10.5 months, with no disease progression after 2 years. Conclusions Combination of docetaxel and tegaserod for anthracycline-resistant triple-negative breast cancer has good clinical effect and relatively mild adverse reactions, which is an ideal adjuvant chemotherapy regimen.